Selection of markers to predict tumour response or survival: Description of a novel approach

European Journal of Cancer

Volumn 35, Issue 12, 1999, Pages 1650-1652

  McLeod, H L ^b   Murray, G I ^b   Mollison, J ^a   McKay, J ^b   Cassidy, J ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033392893     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00182-3     Document Type: Article

References (14)

1. Dowsett M. Improved prognosis for biomarkers in breast cancer. Lancet. 351:1998;1753-1754.
2. Hayes D.F., Bast R.C., Desch C.E.et al. Tumor marker utility grading system - a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 88:1996;1456-1466.
3. Cohen A.M., Tremiterra S., Candela F., Thaler H.T., Sigurdson E.R. Prognosis of node positive colon cancer. Cancer. 67:1991;1859-1861.
4. Kosary C.L. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system - an analysis of 1973-87 seer cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin. Surg. Oncol. 10:1994;31-46.
5. Moertel C.G., Fleming T.R., MacDonald J.S.et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage-III colon carcinoma - a final report. Ann. Intern. Med. 122:1995;321-326.
6. Wei X., McLeod H.L., McMurrough J., Gonzalez F.J., Fernandez Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98:1996;610-615.
7. McLeod H.L., Murray G.I. Tumour markers of prognosis in colorectal cancer. Br. J. Cancer. 79:1999;171-203.
8. Bast R.C., Desch C.E., Hayes D.F.et al. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 16:1998;793-795.
9. Mazurek A., Niklinski J., Laudanski T., Pluygers E. Clinical tumour markers in ovarian cancer. Eur. J. Cancer Prevent. 7:1998;23-35.
10. Gao X., Porter A.T., Grignon D.J., Pontes J.E., Honn K.V. Diagnostic and prognostic markers for human prostate cancer. Prostate. 31:1997;264-281.
11. Niklinski J., Furman M. Clinical tumor markers in lung cancer. Eur. J. Cancer Prevent. 4:1995;129-138.
12. Weinstein J.N., Myers T.G., O'Connor P.M.et al. An information intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349.
13. Boyd M.R., Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34:1995;91-109.
14. Kononen J., Bubendorf L., Kallioniemi A.et al. Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nature Med. 4:1998;844-847.